AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Syntara Ltd

0.026

0.000-1.89%

Volume:704.11K

Turnover:18.09K

Market Cap:51.01M

PE:-3.59

High:0.026

Open:0.026

Low:0.025

Close:0.027

52wk High:0.040

52wk Low:0.019

Shares:1.96B

Float Shares:1.00B

Volume Ratio:0.95

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.007

EPS(LYR):-0.005

ROE:-90.51%

ROA:-47.51%

PB:4.81

PE(LYR):-4.82

Loading ...

Overview Company News Filings

Syntara Ltd-azalox Mds Study Advances to Final Phase 1B Cohort

THOMSON REUTERS

Syntara's Parkinson's-Linked Drug Candidate Shows Encouraging Trial Results, Says Euroz Hartleys

MT Newswires Live

Syntara Seeks Trading Halt

Syntara - Trading Halt Pending Preliminary Results from Irbd Parkinson’s Disease Study of Snt-4728

THOMSON REUTERS

Syntara Ltd-proposed Issue of Securities to the CEO

THOMSON REUTERS

Syntara Completes Share Purchase Plan

MT Newswires Live

Syntara Ltd-Results of Share Purchase Plan

THOMSON REUTERS

Syntara Ltd-Share Purchase Plan Offer Booklet

THOMSON REUTERS

BUZZ-Australia's Syntara loses most in over 8 months on discounted placement

Syntara Ltd-Investor Update Webinar

THOMSON REUTERS

BRIEF-Syntara Announces A$8M Placement And Share Purchase Plan

Syntara Ltd - Capital Raising at a$0.027 per New Share

THOMSON REUTERS

Syntara Ltd - All Figures in AUD

THOMSON REUTERS

Syntara Ltd - to Raise Approx a$2.0 Mln via Share Purchase Plan

THOMSON REUTERS

Syntara Receives Positive US FDA Feedback for Clinical Trial of Bone Marrow Cancer Treatment

MT Newswires Live

BRIEF-Syntara Requests Continuation Of Trading Halt

Syntara Ltd - Trading Halt to Remain Until 29 April 2026 or Capital Raising Announcement

THOMSON REUTERS

Syntara Ltd - Requests Continuation of Trading Halt on ASX: Snt

THOMSON REUTERS

Syntara Ltd-Positive FDA Feedback for Amsulostat P2b Trial

THOMSON REUTERS

BRIEF-Syntara Seeks Trading Halt

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/SNT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SNT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SNT.AU\",,,,,undefined,":{"symbol":"SNT.AU","market":"AU","secType":"STK","nameCN":"Syntara Ltd","latestPrice":0.026,"timestamp":1787292720000,"preClose":0.0265,"halted":0,"volume":704106,"delay":0,"changeRate":-0.018867924528301903,"nameEN":"Syntara Ltd","floatShares":1004676595,"shares":1961906275,"eps":-0.007236,"marketStatus":"Market Closed","change":-0.0005,"latestTime":"08-21 16:12:00 AEST","open":0.026,"high":0.026,"low":0.025,"amount":18090,"amplitude":0.037736,"askPrice":0.027,"askSize":72892,"bidPrice":0.025,"bidSize":577828,"shortable":3,"etf":0,"ttmEps":-0.007236,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.0265,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.9477915472498059,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"SNT.AU","preClose":0.0265,"auctionPrice":0.026,"auctionVolume":1238,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292035822}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SNT.AU\",,,,,undefined,":{"symbol":"SNT.AU","floatShares":1004676595,"roa":"-47.51%","roe":"-90.51%","lyrEps":-0.005389,"volumeRatio":0.9477915472498059,"shares":1961906275,"dividePrice":0,"high":0.026,"amplitude":0.037736,"preClose":0.0265,"low":0.025,"week52Low":0.019,"pbRate":"4.81","psRate":"6.80","week52High":0.04,"institutionHeld":0,"latestPrice":0.026,"committee":0.775965,"eps":-0.007236,"divideRate":0,"volume":704106,"delay":0,"ttmEps":-0.007236,"open":0.026,"prevYearClose":0.035,"prevWeekClose":0.026,"prevMonthClose":0.025,"prevQuarterClose":0.02,"fiveDayClose":0.026,"twentyDayClose":0.022,"sixtyDayClose":0.026},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNT.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-07-28","symbol":"SNT.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1785160800000,"reportTimeType":"","actualEps":null},{"date":"2025-05-01","symbol":"SNT.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1746057600000,"name":null,"time":"","dateTimestamp":1746021600000,"actualEps":null},{"market":"AU","date":"2024-10-29","symbol":"SNT.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1730120400000,"reportTimeType":"pre","actualEps":null},{"date":"2024-04-30","symbol":"SNT.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1714435200000,"name":null,"time":"","dateTimestamp":1714399200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2652268086","title":"Syntara Ltd-azalox Mds Study Advances to Final Phase 1B Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2652268086","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652268086?lang=en_us&edition=fundamental","pubTime":"2026-07-20 08:01","pubTimestamp":1784505714,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUE2TTVLT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNT.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649973672","title":"Syntara's Parkinson's-Linked Drug Candidate Shows Encouraging Trial Results, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2649973672","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649973672?lang=en_us&edition=fundamental","pubTime":"2026-07-07 07:08","pubTimestamp":1783379325,"startTime":"0","endTime":"0","summary":"Syntara's  positive headline results from a Phase 2 trial of its experimental drug for isolated REM Sleep Behaviour Disorder  indicate that the trial objectives were met, Euroz Hartleys said in a note on Monday.The investment firm said the encouraging results confirm that the drug candidate SNT-4728 is safe and well-tolerated.The trial also enrolled iRBD patients who are at a high risk of developing Parkinson's, making the findings more relevant to the drug's potential use in Parkinson's disease.The brokerage sees a significant potential market opportunity due to the lack of approved treatments for iRBD.Euroz Hartleys maintained a speculative buy rating on Syntara with a price target of $0.16.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNT.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648463921","title":"Syntara Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2648463921","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648463921?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:23","pubTimestamp":1783034618,"startTime":"0","endTime":"0","summary":"BRIEF-Syntara Seeks Trading HaltJuly 3 (Reuters)-Syntara LtdSNT.AX:TRADING HALT PENDING PRELIMINARY RESULTS FROM IRBD PARKINSON’S DISEASE STUDY OF SNT-4728Further company coverage:SNT.AX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nFWN4340Y6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648863921","title":"Syntara - Trading Halt Pending Preliminary Results from Irbd Parkinson’s Disease Study of Snt-4728","url":"https://stock-news.laohu8.com/highlight/detail?id=2648863921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648863921?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:23","pubTimestamp":1783034598,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nFWN4340Y6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648632579","title":"Syntara Ltd-proposed Issue of Securities to the CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2648632579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648632579?lang=en_us&edition=fundamental","pubTime":"2026-07-02 12:56","pubTimestamp":1782968168,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nTUE6JJ8XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNT.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642480334","title":"Syntara Completes Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2642480334","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642480334?lang=en_us&edition=fundamental","pubTime":"2026-06-10 14:44","pubTimestamp":1781073851,"startTime":"0","endTime":"0","summary":"Syntara  completed its share purchase plan, with applications received totalling around AU$840,000, and a total of 31.2 million new fully paid ordinary shares will be issued, according to a Wednesday Australian bourse filing.Shares were offered under the plan at an issue price of AU$0.027 apiece.It will use the proceeds alongside the AU$8 million raised via a placement to fund five key clinical trial readouts within the year, to progress current licensing discussions across the pipeline, and to prepare for a phase 2b study.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642441796","title":"Syntara Ltd-Results of Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2642441796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642441796?lang=en_us&edition=fundamental","pubTime":"2026-06-10 13:07","pubTimestamp":1781068053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUE2Z1JGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635754137","title":"Syntara Ltd-Share Purchase Plan Offer Booklet","url":"https://stock-news.laohu8.com/highlight/detail?id=2635754137","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635754137?lang=en_us&edition=fundamental","pubTime":"2026-05-14 07:02","pubTimestamp":1778713350,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUEKJZVN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631552946","title":"BUZZ-Australia's Syntara loses most in over 8 months on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2631552946","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631552946?lang=en_us&edition=fundamental","pubTime":"2026-04-29 11:47","pubTimestamp":1777434421,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Syntara loses most in over 8 months on discounted placement** Shares of Syntara SNT.AX fall as much as 12.5% to A$0.028, their lowest level since November 12, 2025** Stock's biggest intraday pct loss since August 11, 2025** On track for second straight session of losses** Drug developer says it would raise A$2 mln  to fund further clinical trials, among others, through placement** Offer price of A$0.027/share marks 15.6% discount to stock's last close on April 24; Trading halt announced on April 27** Stock down 17.1% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nL6N41C04Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"BUZZ-Australia's Syntara loses most in over 8 months on discounted placement","news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631559832","title":"Syntara Ltd-Investor Update Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2631559832","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631559832?lang=en_us&edition=fundamental","pubTime":"2026-04-29 09:43","pubTimestamp":1777427033,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUE66ZXTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631955577","title":"BRIEF-Syntara Announces A$8M Placement And Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2631955577","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631955577?lang=en_us&edition=fundamental","pubTime":"2026-04-29 09:19","pubTimestamp":1777425552,"startTime":"0","endTime":"0","summary":"BRIEF-Syntara Announces A$8M Placement And Share Purchase PlanApril 29  - Syntara Ltd SNT.AX:A$8M PLACEMENT AND SHARE PURCHASE PLANTO RAISE APPROX A$2.0 MILLION VIA SHARE PURCHASE PLANCAPITAL RAISING AT A$0.027 PER NEW SHAREALL FIGURES IN AUDFurther company coverage: SNT.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUE59B6CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631796558","title":"Syntara Ltd - Capital Raising at a$0.027 per New Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2631796558","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631796558?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:21","pubTimestamp":1777422086,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUE59B6CD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631558794","title":"Syntara Ltd - All Figures in AUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2631558794","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631558794?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:21","pubTimestamp":1777422086,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUE59B6CD:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631558763","title":"Syntara Ltd - to Raise Approx a$2.0 Mln via Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2631558763","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631558763?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:21","pubTimestamp":1777422086,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUE59B6CD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630290993","title":"Syntara Receives Positive US FDA Feedback for Clinical Trial of Bone Marrow Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2630290993","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630290993?lang=en_us&edition=fundamental","pubTime":"2026-04-28 13:28","pubTimestamp":1777354123,"startTime":"0","endTime":"0","summary":"Syntara  received positive feedback from the US Food and Drug Administration following a type C meeting, supporting the design of its planned phase 2b clinical trial of amsulostat for the treatment of myelofibrosis, according to a Tuesday filing with the Australian bourse.The primary endpoint of the phase 2b study will be the achievement of a 50% reduction in the total symptom score following nine months of treatment, with about 100 patients expected to be enrolled, per the filing.The positive feedback from the US FDA allows for amsulostat's progression into late-stage clinical development and paves the way for further engagement with prospective commercial partners, the company said.Myelofibrosis is a type of bone marrow cancer where the accumulation of scar tissue leads to a loss of red and white blood cells and platelets.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNT.AU","BK4585","BK4588","BK7096","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630347036","title":"BRIEF-Syntara Requests Continuation Of Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2630347036","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630347036?lang=en_us&edition=fundamental","pubTime":"2026-04-28 10:08","pubTimestamp":1777342104,"startTime":"0","endTime":"0","summary":"BRIEF-Syntara Requests Continuation Of Trading Halt April 28 (Reuters) - Syntara Ltd SNT.AX:REQUESTS CONTINUATION OF TRADING HALT ON ASX: SNTTRADING HALT TO REMAIN UNTIL 29 APRIL 2026 OR CAPITAL RAISING ANNOUNCEMENTFurther company coverage: SNT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41A1BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630534708","title":"Syntara Ltd - Trading Halt to Remain Until 29 April 2026 or Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630534708","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630534708?lang=en_us&edition=fundamental","pubTime":"2026-04-28 10:07","pubTimestamp":1777342024,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41A1BT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNT.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630083347","title":"Syntara Ltd - Requests Continuation of Trading Halt on ASX: Snt","url":"https://stock-news.laohu8.com/highlight/detail?id=2630083347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630083347?lang=en_us&edition=fundamental","pubTime":"2026-04-28 10:07","pubTimestamp":1777342024,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41A1BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630234777","title":"Syntara Ltd-Positive FDA Feedback for Amsulostat P2b Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2630234777","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630234777?lang=en_us&edition=fundamental","pubTime":"2026-04-28 10:06","pubTimestamp":1777341998,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUEBQF47F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630233023","title":"BRIEF-Syntara Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2630233023","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630233023?lang=en_us&edition=fundamental","pubTime":"2026-04-27 09:21","pubTimestamp":1777252899,"startTime":"0","endTime":"0","summary":"BRIEF-Syntara Seeks Trading HaltApril 27 (Reuters) - Syntara Ltd SNT.AX:TRADING HALT PENDING ANNOUNCEMENT ON FDA CORRESPONDENCE FOR AMSULOSTAT PHASE 2B TRIAL PROTOCOLFurther company coverage: SNT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN4171CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}]}}